Browsing Radiotherapy and Imaging by author "Harrington, Kevin"
Now showing items 81-100 of 158
-
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris, RL; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; et al. (MASSACHUSETTS MEDICAL SOC, 2016-11-10)BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 ... -
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
Ferris, RL; Licitra, L; Fayette, J; Even, C; Blumenschein, G; et al. (AMER ASSOC CANCER RESEARCH, 2019-09-01)PURPOSE: Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic ... -
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Haddad, R; Concha-Benavente, F; Blumenschein, G; Fayette, J; Guigay, J; et al. (WILEY, 2019-09-15)BACKGROUND: Response patterns with immune checkpoint inhibitors may be different from those with chemotherapy. Therefore, assessment of response to immunotherapy with the Response Evaluation Criteria in Solid Tumors (RECIST), ... -
Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.
Saba, NF; Blumenschein, G; Guigay, J; Licitra, L; Fayette, J; et al. (ELSEVIER, 2019-09-01)OBJECTIVES: Many patients with squamous cell carcinoma of the head and neck (SCCHN) are ≥65 years old; comorbidities and other age-related factors may affect their ability to tolerate traditional chemotherapy. Nivolumab ... -
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington, KJ; Ferris, RL; Blumenschein, G; Colevas, AD; Fayette, J; et al. (ELSEVIER SCIENCE INC, 2017-08-01)BACKGROUND: Patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck have few treatment options and poor prognosis. Nivolumab significantly improved survival of this patient ... -
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris, RL; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; et al. (ELSEVIER SCIENCE BV, 2018-06-01)OBJECTIVES: We report 2-year results from CheckMate 141 to establish the long-term efficacy and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with recurrent or metastatic (R/M),platinum-refractory ... -
Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI.
Panek, R; Welsh, L; Baker, LCJ; Schmidt, MA; Wong, KH; et al. (AMER ASSOC CANCER RESEARCH, 2017-08-01)Purpose: To evaluate intrinsic susceptibility (IS) MRI for the identification of cycling hypoxia, and the assessment of its extent and spatial distribution, in head and neck squamous cell carcinoma (HNSCC) xenografts and ... -
Normal Tissue Complication Probability (NTCP) Modelling of Severe Acute Mucositis using a Novel Oral Mucosal Surface Organ at Risk.
Dean, JA; Welsh, LC; Wong, KH; Aleksic, A; Dunne, E; et al. (ELSEVIER SCIENCE LONDON, 2017-04-01)AIMS: A normal tissue complication probability (NTCP) model of severe acute mucositis would be highly useful to guide clinical decision making and inform radiotherapy planning. We aimed to improve upon our previous model ... -
Normal tissue complication probability (NTCP) modelling using spatial dose metrics and machine learning methods for severe acute oral mucositis resulting from head and neck radiotherapy.
Dean, JA; Wong, KH; Welsh, LC; Jones, A-B; Schick, U; et al. (ELSEVIER IRELAND LTD, 2016-07-01)BACKGROUND AND PURPOSE: Severe acute mucositis commonly results from head and neck (chemo)radiotherapy. A predictive model of mucositis could guide clinical decision-making and inform treatment planning. We aimed to generate ... -
NUT Carcinoma of the Salivary Glands: Clinicopathologic and Molecular Analysis of 3 Cases and a Survey of NUT Expression in Salivary Gland Carcinomas.
Agaimy, A; Fonseca, I; Martins, C; Thway, K; Barrette, R; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2018-07-01)NUT carcinoma (NC) represents a rare subset of highly aggressive poorly differentiated carcinomas characterized by rearrangement of the NUT (aka NUTM1, nuclear protein in testis) gene, most commonly fused to BRD4. Originally ... -
On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy.
Nenclares, P; Gunn, L; Soliman, H; Bover, M; Trinh, A; et al. (BMJ PUBLISHING GROUP, 2021-06-01)BACKGROUND: Previous studies have suggested that inflammatory markers (neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH) and fibrinogen) are prognostic biomarkers in patients with a variety of solid cancers, ... -
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.
Annels, NE; Arif, M; Simpson, GR; Denyer, M; Moller-Levet, C; et al. (CELL PRESS, 2018-06-29)As a clinical setting in which local live biological therapy is already well established, non-muscle invasive bladder cancer (NMIBC) presents intriguing opportunities for oncolytic virotherapy. Coxsackievirus A21 (CVA21) ... -
Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.
Samson, A; Bentham, MJ; Scott, K; Nuovo, G; Bloy, A; et al. (BMJ PUBLISHING GROUP, 2018-03-01)OBJECTIVE: Oncolytic viruses (OVs) represent promising, proinflammatory cancer treatments. Here, we explored whether OV-induced innate immune responses could simultaneously inhibit HCV while suppressing hepatocellular ... -
Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors.
Annels, NE; Simpson, GR; Denyer, M; Arif, M; Coffey, M; et al. (CELL PRESS, 2021-03-26)Prostate cancers are considered "cold" tumors characterized by minimal T cell infiltrates, absence of a type I interferon (IFN) signature, and the presence of immunosuppressive cells. This non-inflamed phenotype is likely ... -
Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.
Mansfield, DC; Kyula, JN; Rosenfelder, N; Chao-Chu, J; Kramer-Marek, G; et al. (NATURE PUBLISHING GROUP, 2016-04-01)Oncolytic strains of vaccinia virus are currently in clinical development with clear evidence of safety and promising signs of efficacy. Addition of therapeutic genes to the viral genome may increase the therapeutic efficacy ... -
Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis.
Wilkinson, MJ; Smith, HG; McEntee, G; Kyula-Currie, J; Pencavel, TD; et al. (IMPACT JOURNALS LLC, 2016-12-06)Advanced extremity melanoma and sarcoma present a significant therapeutic challenge, requiring multimodality therapy to treat or even palliate disease. These aggressive tumours are relatively chemo-resistant, therefore new ... -
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.
Kottke, T; Tonne, J; Evgin, L; Driscoll, CB; van Vloten, J; et al. (NATURE PORTFOLIO, 2021-03-26)In our clinical trials of oncolytic vesicular stomatitis virus expressing interferon beta (VSV-IFNβ), several patients achieved initial responses followed by aggressive relapse. We show here that VSV-IFNβ-escape tumors ... -
Online adaptive radiotherapy for head and neck cancers on the MR linear Accelerator: Introducing a novel modified Adapt-to-Shape approach.
Gupta, A; Dunlop, A; Mitchell, A; McQuaid, D; Nill, S; et al. (ELSEVIER IRELAND LTD, 2021-11-19)INTRODUCTION: The Elekta Unity MR-Linac (MRL) has enabled adaptive radiotherapy (ART) for patients with head and neck cancers (HNC). Adapt-To-Shape-Lite (ATS-Lite) is a novel Adapt-to-Shape strategy that provides ART without ... -
Optimal acquisition scheme for flow-compensated intravoxel incoherent motion diffusion-weighted imaging in the abdomen: An accurate and precise clinically feasible protocol.
Gurney-Champion, OJ; Rauh, SS; Harrington, K; Oelfke, U; Laun, FB; et al. (WILEY, 2020-03-01)PURPOSE: Flow-compensated (FC) diffusion-weighted MRI (DWI) for intravoxel-incoherent motion (IVIM) modeling allows for a more detailed description of tissue microvasculature than conventional IVIM. The long acquisition ... -
Patient-reported outcomes with nivolumab in advanced solid cancers.
Tykodi, SS; Schadendorf, D; Cella, D; Reck, M; Harrington, K; et al. (ELSEVIER SCI LTD, 2018-11-01)Patients with recurrent or metastatic cancer commonly suffer from debilitating toxicity associated with conventional treatment modalities, as well as disease-related symptoms, often with a concomitant negative impact on ...